Practical Considerations for the Use of Sodium-Glucose Co-Transporter 2 Inhibitors in Heart Failure

Practical Guide to Prescribing Sodium-Glucose Cotransporter 2 Inhibitors for Cardiologists

(2019) Orly Vardeny et al.   JACC-Heart Failure

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

(2019) Vlado Perkovic et al.   NEW ENGLAND JOURNAL OF MEDICINE

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

(2019) Brendon L Neuen et al.   Lancet Diabetes & Endocrinology

Medical Therapy for Heart Failure With Reduced Ejection Fraction

(2018) Stephen J. Greene et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Prescriber Patterns of SGLT2i After Expansions of U.S. Food and Drug Administration Labeling

(2018) Muthiah Vaduganathan et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

(2018) Sandeep R. Das et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

(2018) Thomas A Zelniker et al.   LANCET

Initiation, Continuation, Switching, and Withdrawal of Heart Failure Medical Therapies During Hospitalization

(2018) Aditi A. Bhagat et al.   JACC-Heart Failure